↓ Skip to main content

Quality of life in patients with retinitis pigmentosa submitted to intravitreal use of bone marrow-derived stem cells (Reticell -clinical trial)

Overview of attention for article published in Stem Cell Research & Therapy, March 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 tweeter
facebook
2 Facebook pages

Citations

dimensions_citation
79 Dimensions

Readers on

mendeley
100 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Quality of life in patients with retinitis pigmentosa submitted to intravitreal use of bone marrow-derived stem cells (Reticell -clinical trial)
Published in
Stem Cell Research & Therapy, March 2015
DOI 10.1186/s13287-015-0020-6
Pubmed ID
Authors

Rubens C Siqueira, Andre Messias, Katharina Messias, Rafael S Arcieri, Milton A Ruiz, Neiglene F Souza, Lia C Martins, Rodrigo Jorge

Abstract

Retinitis pigmentosa (RP) is a severe neurodegenerative disease of the retina that can lead to blindness. Even without treatment, a clinical study with the use of stem cells is currently underway and the results are being evaluated. In the present report we assess the vision-related quality of life in patients with RP submitted to intravitreal use of bone marrow-derived stem cells. The study included 20 patients with RP submitted to intravitreal use of bone marrow-derived stem cells. We evaluate the vision-related quality of life (VRQOL) of patients using the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25). Patients were scheduled to answer the questionnaire before treatment and 3 and 12 months after treatment. All patients completed the survey as scheduled. There was a statistically significant improvement (P <0.05) in the quality of life of patients 3 months after treatment, whereas by the 12th month there was no statistically significant difference from baseline. Cell therapy with intravitreal use of bone marrow-derived stem cells can improve the quality of life of patients with RP, although the improvement is lost with time. A larger number of cases will be necessary to evaluate the repercussions of this therapy on the quality of life of these patients. Clinicaltrials.gov: NCT01560715 . Registered March 19, 2012.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 100 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
France 1 1%
Germany 1 1%
Unknown 97 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 16%
Student > Bachelor 14 14%
Other 9 9%
Student > Master 9 9%
Student > Ph. D. Student 7 7%
Other 21 21%
Unknown 24 24%
Readers by discipline Count As %
Medicine and Dentistry 26 26%
Biochemistry, Genetics and Molecular Biology 9 9%
Neuroscience 8 8%
Agricultural and Biological Sciences 8 8%
Engineering 5 5%
Other 15 15%
Unknown 29 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 August 2016.
All research outputs
#5,922,837
of 8,183,022 outputs
Outputs from Stem Cell Research & Therapy
#482
of 667 outputs
Outputs of similar age
#129,773
of 203,087 outputs
Outputs of similar age from Stem Cell Research & Therapy
#37
of 47 outputs
Altmetric has tracked 8,183,022 research outputs across all sources so far. This one is in the 24th percentile – i.e., 24% of other outputs scored the same or lower than it.
So far Altmetric has tracked 667 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 203,087 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.